Ge Long Hui·2026-02-09 22:43Core Viewpoint - China Biologic Products (01177.HK) has announced that its self-developed innovative drug TQB2102, a HER2 dual-target antibody-drug conjugate (ADC), is currently undergoing a Phase III clinical trial to evaluate its efficacy and safety compared to chemotherapy in HER2 low-expressing recurrent/metastatic breast cancer [1][2]. Group 1 - TQB2102 is a next-generation HER2 dual epitope bispecific antibody-drug conjugate developed by the company, which optimizes the balance between efficacy and safety through three core technological innovations [2]. - The first innovation is the dual epitope targeting design, which employs an asymmetric structural design for the antibody end, significantly enhancing selectivity for tumor cells and drug internalization efficiency, thereby increasing anti-tumor activity [2]. - The second innovation involves a cleavable linker that efficiently releases toxins and possesses a "bystander effect," which helps eliminate surrounding heterogeneous tumor cells, thus expanding the killing range [2]. - The third innovation is the optimized drug-antibody ratio (DAR), which is stably controlled between 5.8 and 6.0, combined with a topoisomerase I (Topo I) inhibitor toxin, enhancing efficacy while reducing side effects [2]. - The combination of these core technologies breaks through the limitations of traditional HER2 monoclonal antibodies and single-target ADCs, demonstrating significant potential for TQB2102 in treating HER2 low-expressing tumors [2].